NCR2 and melanoma: Both melanoma and hepatocellular carcinoma cells are able to inhibit the expression of NK receptors that trigger their immune function, including NKp30, NKp44, and NKG2D, with the impairment of NK-cell-mediated cytolytic activity against melanoma cells, through IDO1 and PGE2 expression [190,191].